title: Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.
abstract: Platinum agents have been widely used in cancer chemotherapy for a long time. Cisplatin, carboplatin, oxaliplatin and nedaplatin have a common chemical structure consisting of platinum, carrier groups and leaving groups, and undergo the similar mechanism of cytotoxicity. However, each agent differs in its efficacy and adverse effects, although the molecular mechanism involved is unclear. Recently, it was reported that organic cation transporter OCT/SLC22A, and multidrug and toxin extrusion MATE/SLC47A play a role in the pharmacokinetics of platinum agents. Only cisplatin induces nephrotoxicity and the toxicity is kidney-specific. Kidney-specific OCT2 mediates the transport of cisplatin and is the determinant of cisplatin-induced nephrotoxicity. In addition, cisplatin and oxaliplatin are substrates for these transporters, but carboplatin and nedaplatin are not. Substrate specificity could regulate the features of platinum agents. In this commentary, we will discuss the characteristics of OCT and MATE, and demonstrate the recent topics about the relationship between the transport of platinum agents by organic cation transporters and their pharmacological characteristics.
authors.affiliation: Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yonezawa
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Inui
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000378:metabolism; D017920:Antiporters / Q000502:physiology*; D001692:Biological Transport; D016190:Carboplatin / Q000009:adverse effects* / Q000378:metabolism; D002945:Cisplatin / Q000009:adverse effects* / Q000378:metabolism; D006801:Humans; D027701:Organic Cation Transport Proteins / Q000502:physiology*; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000378:metabolism; D000077150:Oxaliplatin; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D017920:Antiporters; D027701:Organic Cation Transport Proteins; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C053989:nedaplatin; D016190:Carboplatin; D002945:Cisplatin